Form 8-K - Current report:
SEC Accession No. 0001193125-22-282637
Filing Date
2022-11-10
Accepted
2022-11-10 16:18:45
Documents
13
Period of Report
2022-11-10
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d379228d8k.htm   iXBRL 8-K 28814
2 EX-3.1 d379228dex31.htm EX-3.1 8525
  Complete submission text file 0001193125-22-282637.txt   170306

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alrn-20221110.xsd EX-101.SCH 2865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20221110_lab.xml EX-101.LAB 19485
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20221110_pre.xml EX-101.PRE 12160
7 EXTRACTED XBRL INSTANCE DOCUMENT d379228d8k_htm.xml XML 3770
Mailing Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210
Business Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 221377510
SIC: 2834 Pharmaceutical Preparations